Popławski Piotr, Wiśniewski Jacek R, Rijntjes Eddy, Richards Keith, Rybicka Beata, Köhrle Josef, Piekiełko-Witkowska Agnieszka
Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Biochemical Proteomics Group, Max-Planck-Institute of Biochemistry, Martinsried, Germany.
PLoS One. 2017 Dec 22;12(12):e0190179. doi: 10.1371/journal.pone.0190179. eCollection 2017.
Type 1 iodothyronine deiodinase (DIO1) contributes to deiodination of 3,5,3',5'-tetraiodo-L-thyronine (thyroxine, T4) yielding of 3,5,3'-triiodothyronine (T3), a powerful regulator of cell differentiation, proliferation, and metabolism. Our previous work showed that loss of DIO1 enhances proliferation and migration of renal cancer cells. However, the global effects of DIO1 expression in various tissues affected by cancer remain unknown. Here, the effects of stable DIO1 re-expression were analyzed on the proteome of renal cancer cells, followed by quantitative real-time PCR validation in two renal cancer-derived cell lines. DIO1-induced changes in intracellular concentrations of thyroid hormones were quantified by L-MS/MS and correlations between expression of DIO1 and potential target genes were determined in tissue samples from renal cancer patients. Stable re-expression of DIO1, resulted in 26 downregulated proteins while 59 proteins were overexpressed in renal cancer cells. The 'downregulated' group consisted mainly of oncoproteins (e.g. STAT3, ANPEP, TGFBI, TGM2) that promote proliferation, migration and invasion. Furthermore, DIO1 re-expression enhanced concentrations of two subunits of thyroid hormone transporter (SLC7A5, SLC3A2), enzymes of key pathways of cellular energy metabolism (e.g. TKT, NAMPT, IDH2), sex steroid metabolism and anti-oxidative response (AKR1C2, AKR1B10). DIO1 expression resulted in elevated intracellular concentration of T4. Expression of DIO1-affected genes strongly correlated with DIO1 transcript levels in tissue samples from renal cancer patients as well as with their poor survival. This first study addressing effects of deiodinase re-expression on proteome of cancer cells demonstrates that induced DIO1 re-expression in renal cancer robustly downregulates oncoproteins, affects key metabolic pathways, and triggers proteins involved in anti-oxidative protection. This data supports the notion that suppressed DIO1 expression and changes in local availability of thyroid hormones might favor a shift from a differentiated to a more proliferation-prone state of cancer tissues and cell lines.
1型碘甲状腺原氨酸脱碘酶(DIO1)有助于将3,5,3',5'-四碘-L-甲状腺原氨酸(甲状腺素,T4)脱碘生成3,5,3'-三碘甲状腺原氨酸(T3),T3是细胞分化、增殖和代谢的强大调节因子。我们之前的研究表明,DIO1缺失会增强肾癌细胞的增殖和迁移能力。然而,DIO1在受癌症影响的各种组织中的整体作用仍不清楚。在此,我们分析了稳定重新表达DIO1对肾癌细胞蛋白质组的影响,随后在两种源自肾癌的细胞系中进行了定量实时PCR验证。通过液相色谱-串联质谱(LC-MS/MS)对DIO1诱导的甲状腺激素细胞内浓度变化进行了定量,并在肾癌患者的组织样本中确定了DIO1表达与潜在靶基因之间的相关性。DIO1的稳定重新表达导致肾癌细胞中有26种蛋白质表达下调,而59种蛋白质表达上调。“下调”组主要由促进增殖、迁移和侵袭的癌蛋白(如STAT3、ANPEP、TGFBI、TGM2)组成。此外,DIO1的重新表达提高了甲状腺激素转运体的两个亚基(SLC7A5、SLC3A2)、细胞能量代谢关键途径的酶(如TKT、NAMPT、IDH2)、性类固醇代谢和抗氧化反应(AKR1C2、AKR1B10)的浓度。DIO1的表达导致细胞内T4浓度升高。在肾癌患者的组织样本中,受DIO1影响的基因表达与DIO1转录水平以及患者的不良生存率密切相关。这项首次研究脱碘酶重新表达对癌细胞蛋白质组影响的研究表明,在肾癌中诱导DIO1重新表达可强烈下调癌蛋白,影响关键代谢途径,并触发参与抗氧化保护的蛋白质。这些数据支持这样一种观点,即DIO1表达受抑制以及甲状腺激素局部可用性的变化可能有利于癌症组织和细胞系从分化状态转变为更易于增殖的状态。